From sustainability to urgency: a product lifecycle mindset for PSP and EAP

A drug's lifecycle services span from pre-launch clinical trials through to post-approval commercialization, but the core issue is always the same: solving patients' access to medicine. As new drugs reach the market ever faster, a more strategic concept of patient support services has emerged — the Patient Solution has evolved from the PSP (Patient Support Program) to the market frontier of the EAP (Expanded Access Program).

The core of a Patient Support Program (PSP) is a sustainable journey focused on helping patients "use their medicine well." It is a long-term service that spans the period before and after drug approval, designed to help patients obtain the treatment they need, improve medication adherence, manage side effects, and provide practical daily-life and financial support. A well-designed PSP can significantly improve clinical outcomes and ensure a drug's efficacy is both "seen" and "sustained" in the real world. The first-hand real-world data gathered through close interaction with patients and providers in a PSP becomes an intangible asset for drug development.

When a pharmaceutical company prepares to launch a next-generation drug or a new indication, the data and insights accumulated through the PSP come into play. These insights can feed back into the design of new formulations or indications. The EAP, by contrast, is an approved pre-launch mechanism for emergency use — a reactive channel for meeting urgent patient needs — yet viewed across the product lifecycle, it is all the more targeted and strategic.

A closed service loop driven by the physician's treatment plan

As a Patient Solution Provider, PatientsForce understands that EAP and PSP are not isolated service projects: both begin with the physician's treatment plan, in response to patient needs.

Where the PSP begins: the moment a physician writes a prescription, the PSP journey starts. PatientsForce steps in at this point, providing end-to-end support — from medication education and reimbursement navigation to financial assistance and dosing reminders — ensuring patients can smoothly and continuously follow their physician's treatment plan.
The EAP as a reverse extension: when a physician judges a patient's condition to be critical and existing treatment options have failed, PatientsForce can draw on patient journey data accumulated through PSPs to help the medical team navigate the complex EAP application process, monitor medication safety, and secure a stable drug supply — freeing physicians to focus on the core medical decisions.

This patient-centered service model, driven by the physician's treatment plan, seamlessly links EAP and PSP into a strategic closed loop of "value / evidence / access":

Value: through the PSP, real-world treatment outcomes are continuously collected, making the value of the medicine tangible.
Evidence: this valuable data becomes the basis for dialogue with HTA bodies (health economics and payer communications), while pointing the way to more precise solutions.
Access: EAP data in turn becomes evidence for further clinical outcomes, accelerating approval of new drugs or new indications and thereby expanding access.

The value a Patient Solution Provider brings: from compliance to provability

A successful PSP practice is not merely an executor of processes but a strategic enabler. PatientsForce has internalized five core modules into its services:

Unmet Needs Segmentation: precisely identifying the patients in greatest need and tailoring services to their treatment journey.
Evidence & Funding Pathway: helping pharmaceutical companies translate PSP data into language payers understand, and participating in the design of Managed Access Agreements.
Compliance & Risk: embedding rigorous anti-kickback, pharmacovigilance (PV) and data protection (e.g. DPIA) processes to ensure services operate at the highest compliance standards.
Service & Operations: integrating multiple channels to deliver "fast onboarding" and "continuous support" services, with contact rates, adherence and treatment outcomes as key performance indicators (KPIs).
Data & Insight: building standardized data collection frameworks that turn patient-reported outcomes (PROs) and treatment results into data, providing verifiable insights for pharmaceutical companies' commercial decisions.

The PSP secures the sustainability of "using medicine well, proving it works, and keeping it affordable," while the EAP builds on that foundation to solve the urgency of "getting the medicine first." From a business management perspective, true competitiveness lies not in optimizing any single link, but in integrating regulatory compliance, evidence generation, payer dialogue and service design into one complete, patient-centered closed loop.

PatientsForce works with multinational pharmaceutical companies, under rigorous compliance management, to help physicians and patients with patient support services spanning EAP to PSP.

Note:

EAP stands for Early Access Program. It refers to giving patients with serious, life-threatening diseases who have exhausted all other effective treatment options a conditional, supervised opportunity to use a drug or therapy before it has been formally approved by the regulator. The EAP is a special humanitarian mechanism that allows patients, outside of clinical trials, to obtain and use new drugs still in development to meet urgent medical needs. Taiwan has a corresponding special-case drug access system.

Each country has its own name and rules for EAPs, but the underlying spirit is similar:

US FDA: Expanded Access (also known as Compassionate Use)
EU EMA: Compassionate Use Programme
UK MHRA: Early Access to Medicines Scheme (EAMS)
Health Canada: Special Access Programme (SAP)